Telomir Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
TELO$0.71-9.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash | $5,560,511 | $7,286,670 |
| Prepaid expenses | 229,025 | 54,691 |
| Total current assets | 5,789,536 | 7,341,361 |
| Total assets | $5,789,536 | $7,341,361 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Trade accounts payable and accrued liabilities | $279,615 | $536,769 |
| Due to officer | — | 155,518 |
| Accrued compensation - officer | — | 417,470 |
| Insurance loan payable | 202,869 | — |
| Due to related parties | 344,826 | 318,234 |
| Total current liabilities | 827,310 | 1,427,991 |
| Total liabilities | 827,310 | 1,427,991 |
| Commitments and contingencies (Note 8) | - | |
| Stockholders’ Equity: | ||
| Preferred Stock, no par value, 100,000,000 shares authorized | ||
| and none issued or outstanding. | — | — |
| Common Stock, no par value; 300,000,000 shares authorized, 34,380,971 and | ||
| 34,380,971 shares issued and outstanding at March 31, 2026 and | ||
| December 31, 2025, respectively. | — | — |
| Additional paid-in capital | 46,963,236 | 46,923,433 |
| Accumulated deficit | (42,001,010) | (41,010,063) |
| Total stockholders’ equity | 4,962,226 | 5,913,370 |
| Total liabilities and stockholders’ equity | $5,789,536 | $7,341,361 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.